Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting
2022年10月12日 - 9:12PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company
advancing new treatments for patients suffering from serious
diseases underserved by current therapies, today announced that
three abstracts highlighting the potential benefits of VRDN-001
will be presented as oral highlighted and late-breaking poster
presentations at the 91st Annual Meeting of the American Thyroid
Association (ATA), to be held in Montreal, Canada from October 19
to 23, 2022.
“We’re excited to share mechanistic and clinical data at this
year’s ATA annual meeting that contribute to the emerging body of
evidence demonstrating differentiation of VRDN-001 from current
therapies," stated Jonathan Violin, Ph.D., Viridian Therapeutics’
President and CEO. “We are thrilled that the 10 mg/kg data from our
Phase 1/2 trial was selected for a late-breaking presentation, and
we look forward to presenting additional updates for both VRDN-001
and VRDN-002 later this quarter. These updates will include
top-line data for the 20 mg/kg cohort of our ongoing Phase 1/2
trial of VRDN-001 in Thyroid Eye Disease, followed later this
quarter by top-line data from the currently enrolling 3mg/kg
cohort. This quarter we’ll also share additional pharmacokinetic
and pharmacodynamic results from our first-in-human trial of
VRDN-002, our half-life extended IGF-1R antibody, which reinforce
and build upon the recently presented interim results.”
Oral Highlighted Poster Session Details:
Title: |
VRDN-001, a
Full Antagonist Antibody to the Insulin-Like Growth Factor
Receptor-1 (IGF-1R) in Development for Thyroid Eye Disease (TED),
Binds to a Distinct Epitope from Teprotumumab |
Poster: |
#132 |
Session: |
#4 - Non-Thyroid Cancer Highlighted Posters |
Time and Date: |
Thursday, October 20, 2022, 4:00 p.m. to 4:30 p.m. ET |
Room: |
511-CF |
Late-Breaking Poster Session Details:
Title: |
VRDN-001, a
Full Antagonist Antibody to the Insulin-Like Growth Factor
Receptor-1 (IGF-1R) in Development for Thyroid Eye Disease (TED):
Phase 1/2 Proof of Concept in Patients with TED |
Poster: |
#535 |
Date and Time: |
Friday, October 21, 2022,11:00 a.m.- 2:30 p.m. ET |
_________________________________________________________________________
Title: |
VRDN-001, a
Full Antagonist Antibody to the Insulin-Like Growth Factor
Receptor-1 (IGF-1R) in Development for Thyroid Eye Disease (TED),
Binds to a Distinct Epitope from Teprotumumab |
Poster: |
#132 |
Time and Date: |
Saturday, October 22, 2022, 10:30 a.m. - 2:30 p.m. ET |
_________________________________________________________________________
Title: |
VRDN-001, A
Potent and Selective Insulin-Like Growth Factor-1 Receptor (IGF-1R)
Antagonist Antibody for Thyroid Eye Disease (TED): Interim Phase 1
Safety and Pharmacodynamic Results in Healthy Volunteers |
Poster: |
#568 |
Time and Date: |
Saturday, October 22, 2022, 10:30 a.m. - 2:30 p.m. ET |
About Viridian Therapeutics,
Inc.Viridian Therapeutics is a biotechnology company
advancing new treatments for patients suffering from serious
diseases underserved by current therapies. Viridian’s most advanced
program, VRDN-001, is a differentiated monoclonal antibody
targeting insulin-like growth factor-1 receptor (IGF-1R), a
clinically and commercially validated target for the treatment of
thyroid eye disease (TED). VRDN-002 is a distinct anti-IGF-1R
antibody and incorporates half-life extension technology. VRDN-003
is an extended half-life version of VRDN-001. Both VRDN-002 and
VRDN-003 are designed for administration as convenient, low-volume,
subcutaneous injections. TED is a debilitating autoimmune disease
that causes inflammation and fibrosis within the orbit of the eye
which can cause double vision, pain, and potential blindness.
Viridian is based in Waltham, Massachusetts.
Note Regarding Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements may be identified by the use of words such as, but
not limited to, "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "might," "plan,"
"potential," "predict," "project," "should," "target," "will," or
"would" or other similar terms or expressions that concern the
Company’s expectations, plans and intentions. Forward-looking
statements include, without limitation, statements regarding the
Company’s expectations, strategies, plans and intentions.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on the
Company’s current beliefs, expectations, and assumptions. New risks
and uncertainties may emerge from time to time, and it is not
possible to predict all risks and uncertainties. No representations
or warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements. Such forward-looking
statements are subject to a number of material risks and
uncertainties including but not limited to results of ongoing
clinical trials; the timing of clinical trial activities and
reporting results from the same, including those risks set forth
under the caption “Risk Factors” in the Company’s Annual Report on
Form 10-K filed with the Securities and Exchange
Commission (SEC) on March 11, 2022 and other
subsequent disclosure documents filed with the SEC. Any
forward-looking statement speaks only as of the date on which it
was made. Neither the Company, nor its affiliates, advisors, or
representatives, undertake any obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by law.
These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date hereof.
Investor & Media Contact:John
JordanViridian TherapeuticsVice President, Investor Relations and
Corporate Communications617-272-4691IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 6 2024 まで 7 2024
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 7 2023 まで 7 2024